The CML cell line K562 has amplifications in the c-myc and l-myc oncogenes but is resistant, compared to all the other leukemia and lymphoma cell lines so far tested, to Chk1 inhibitors as single agents. This evidence concerns the gene MYCL and chronic myelogenous leukemia, BCR-ABL1 positive.